Emergence of synthetic drugs in South America: insights from Brazil, Chile, and Colombia.
Ignacio Bórquez, Bruno Pantaleão, Gabriela Brogim, Ana Paula Da Cunha, Noa Krawczyk, Francisco I Bastos
Harm Reduction Journal June 4, 2026 DOI: 10.1186/s12954-026-01480-4 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Topics | Ketamine |
| Keywords | Harm reduction Nitazenes Novel psychoactive substances Opioids South america Synthetic drugs Tusi |
| Key points | The authors argue that South America is entering a new synthetic drug phase, marked by rising non-prescribed opioid use in Brazil and Chile, fentanyl analogs found in Colombian ketamine and MDMA/Ecstasy samples, nitazene production documented in Brazil in May 2025, and rapidly expanding ketamine and Tusi use. They contend that Tusi's unpredictable composition and the region's minimal opioid agonist therapy coverage, limited naloxone access, and underdeveloped harm reduction systems heighten overdose risks. |
Abstract
The illicit drug landscape in South America is going through a major shift. The appearance of Tusi (or "pink cocaine"), a mixture often containing ketamine and MDMA, along with the growing presence of synthetic opioids like fentanyl and nitazenes, signals a new chapter in the region's drug use, which has been traditionally dominated by alcohol, cannabis, and cocaine. Drawing on data on seizures, forensic analyses, warning systems, and surveys from Brazil, Chile, and Colombia, this perspective highlights three movements of the drug supply: non-prescribed and synthetic opioids, ketamine, and Tusi. We also elaborate on their unique public health challenges. Brazil and Chile have seen an increase in non-prescribed opioid use, some of them diverted from healthcare, accompanied by seizures of illicit fentanyl and the discovery of nitazene production in Brazil in May 2025. Colombia, while historically experiencing low opioid use, has documented fentanyl analogs in ketamine and MDMA/Ecstasy samples, mixed with various other contaminants, thus increasing risks among people who use them. Concurrently, ketamine and Tusi use are expanding rapidly across all three countries, particularly among nightclub attendees and youth with criminal-legal involvement. Tusi's unpredictable composition poses heightened overdose risks, especially in settings lacking drug-checking and overdose-prevention education and programs. Furthermore, South America has minimal opioid agonist therapy coverage, limited naloxone access, and underdeveloped harm reduction systems. The emergence of synthetic opioids, ketamine, and Tusi signals a new synthetic drug phase in South America's supply. The convergence of traditional drugs with potent new substances poses important health-related harms. Strengthening regional surveillance, toxicological monitoring, and harm reduction services are urgently needed. Coordinated international research and public health responses will be essential to prevent a drug crisis.
Citations in the library
Cites 5
- Tusi: a new ketamine concoction complicating the drug landscape. The American Journal of Drug and Alcohol Abuse September 3, 2023
- Tusi use among the New York City nightclub-attending population. Addiction April 20, 2025
- Rare but relevant: Ketamine-induced cystitis - an in-depth review for addiction medicine. Addiction April 4, 2025
- Monstrous substance: 'Tuci', pharmacopolitical assemblages and spectral materialities. International Journal of Drug Policy November 1, 2025
- Tusi but not 2C: A Miami-Dade medical examiner case series highlighting the variable drug composition in colored powder paraphernalia. Journal of Forensic Sciences May 1, 2025